MOTS-c or SS-31?
Mitochondrial research covers very different compounds, populations and outcomes. Here is what belongs to each.
The short answer
MOTS-c’s cited performance research involved dosing mice and observing endogenous peptide changes in exercising humans. SS-31, or elamipretide, has clinical trials and a narrowly defined approved product. Neither establishes a general longevity benefit for the compounded options here.
MOTS-c and SS-31 are not currently offered through AnthologyRX. This comparison remains available for general information.
Side by side
| MOTS-c | SS-31 / elamipretide | |
|---|---|---|
| Research cited | Administered peptide in mice; human exercise observations | Trials in defined mitochondrial diseases |
| Key distinction | No human dosing efficacy result in the cited study | Disease-specific findings do not establish general wellness effects |
| Approval boundary | Not an approved finished medicine here | Forzinity approval does not approve compounded SS-31 |
What the evidence shows
MMPOWER-3 did not meet its primary walking-distance and fatigue endpoints in primary mitochondrial myopathy. FDA’s Forzinity snapshot concerns Barth syndrome and distinguishes the initial randomized findings from strength observations during the open-label extension. Neither is a study of healthy adults seeking more stamina.
Read: Reynolds et al. MOTS-c, exercise and aging; Karaa et al. MMPOWER-3 elamipretide trial; FDA: Forzinity trial snapshot; FDA: Compounding questions and answers.
What matters for your decision
Ask which diagnosis and outcome make the research relevant to you, whether the preparation matches the study and what uncertainty remains. A shared mitochondrial theme is not evidence that the products are substitutes or a beneficial combination.
Questions
Does FDA approval of Forzinity apply to every SS-31 product?
No. Approval belongs to a specific finished product and indication. It does not establish equivalent performance for a compounded preparation.
Sources
- Reynolds et al. MOTS-c, exercise and aging
Nature Communications, 2021. Administered peptide in mice; endogenous peptide observations in humans.
- Karaa et al. MMPOWER-3 elamipretide trial
Neurology, 2023. Primary mitochondrial myopathy; primary walking and fatigue outcomes not met.
- FDA: Forzinity trial snapshot
Elamipretide approval for a specific Barth syndrome population, not general longevity.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
